Myelodysplastic Syndrome Diagnosis and Evaluation

What Are Stem Cells? A Guide to Regenerative Medicine

Stem cells can develop into many cell types and act as the body’s repair system. They replace or restore damaged tissues, offering new possibilities for treating diseases.

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Doctors

The Diagnostic Detective Work

The Diagnostic Detective Work

Diagnosing Myelodysplastic Syndromes is a meticulous process that requires distinguishing actual bone marrow failure from a host of other conditions that can mimic it. Vitamin deficiencies (B12, Folate), copper deficiency, viral infections (HIV, Parvovirus), autoimmune disorders, and medication side effects can all cause low blood counts and dysplastic-looking cells. Therefore, the diagnosis of MDS is often a “diagnosis of exclusion” combined with positive evidence of clonality.

The evaluation process is multi-tiered, moving from non-invasive blood tests to invasive bone marrow sampling, and finally to sophisticated genetic sequencing. This comprehensive workup is essential not only for naming the disease but also for assigning a prognosis. In the era of precision medicine, knowing the specific molecular drivers of a patient’s MDS is crucial for selecting the right therapeutic approach, particularly when considering regenerative stem cell transplantation.

Icon LIV Hospital

Peripheral Blood Analysis

Peripheral Blood Analysis

The initial clue almost always comes from the Complete Blood Count (CBC).

  • Cytopenias: The hallmark finding is a reduction in one or more blood cell lines. Macrocytic anemia (large red blood cells) is a ubiquitous feature.
  • Reticulocyte Count: This measures the number of young red blood cells newly released from the marrow. In MDS, the reticulocyte count is typically low, reflecting the marrow’s inability to produce healthy cells (ineffective erythropoiesis), despite the anemia.
  • Peripheral Blood Smear: A pathologist examines a drop of blood under a microscope. They look for specific “dysplastic” features: red blood cells that are oval-shaped or teardrop-shaped; neutrophils that are hypolobated (Pseudo-Pelger-Huët anomaly) or hypogranular (pale); and giant platelets. The presence of circulating blasts (immature cells) in the blood is a significant finding that triggers urgent marrow evaluation.
Icon 1 LIV Hospital

Bone Marrow Aspiration and Biopsy

Bone Marrow Aspiration and Biopsy

The definitive diagnosis requires direct examination of the bone marrow. This procedure is typically performed at the posterior iliac crest (the back of the hip bone).

  • The Aspirate: The liquid portion of the marrow is withdrawn. This allows the pathologist to look at individual cells in great detail to assess morphology. They count 500 cells to determine the blast percentage and look for dysplasia in the erythroid, myeloid, and megakaryocytic lineages. Dysplasia must be present in at least 10% of the cells of a lineage to qualify as MDS.
  • The Biopsy: A solid core of bone is removed. This preserves the architecture of the marrow. It allows assessment of cellularity (how crowded the marrow is). MDS marrow is typically hypercellular or normocellular. It also helps rule out fibrosis (scarring) or infiltration by other cancers.
  • Iron Stain: A special stain (Prussian Blue) is used on the aspirate to detect “ring sideroblasts,” which are red cell precursors with iron-loaded mitochondria forming a ring around the nucleus.

Cytogenetics: The Chromosomal Blueprint

Diagnosis and Evaluation img 4 6 LIV Hospital

Once cells are obtained, they are cultured and their chromosomes are analyzed. This is known as karyotyping.

  • Importance: Chromosomal abnormalities are found in about 50% of de novo MDS cases and 80% of therapy-related MDS.
  • Common Abnormalities: Common findings include deletions of 5q, 7q, and 20q, and trisomy 8.
  • Prognostic Value: This is the single most important prognostic factor. Patients with del(5q) have a good prognosis, while those with monosomy seven or complex karyotypes (more than three abnormalities) have an inferior prognosis and high risk of leukemic transformation. This directly influences the decision to proceed to transplant.

Molecular Genetics and Next-Generation Sequencing (NGS)

Molecular Genetics and Next-Generation Sequencing (NGS)

In patients with a normal karyotype, molecular testing has become indispensable. NGS allows for the scanning of dozens of genes known to be mutated in myeloid diseases.

  • Diagnostic Utility: Finding a mutation in a gene such as SF3B1, TET2, ASXL1, or DNMT3A confirms that the disease is clonal (cancerous) rather than a reactive condition, helping confirm the MDS diagnosis in complex cases.
  • Prognostic Utility: Certain mutations, like TP53, ASXL1, and RUNX1, are associated with aggressive disease and poor outcomes. Conversely, SF3B1 is associated with a more favorable course (often linked to ring sideroblasts).
  • Therapeutic Targets: Knowing the mutation profile helps in selecting clinical trials or specific targeted therapies (e.g., IDH1/IDH2 inhibitors if those mutations are present, though more common in AML).

Prognostic Scoring Systems

Prognostic Scoring Systems

Once all the data is gathered, clinicians use scoring systems to risk-stratify the patient. The most widely used is the IPSS-R (Revised International Prognostic Scoring System).

  • Variables: These include the depth of cytopenias (how low hemoglobin, platelets, and neutrophils are), the percentage of marrow blasts, and specific cytogenetic abnormalities.
  • Outcome: It places patients into five risk groups: Very Low, Low, Intermediate, High, and Very High.
  • Decision Making: This score is the compass for treatment. Lower-risk patients are generally managed with supportive care or low-intensity drugs to improve blood counts. Higher-risk patients are candidates for disease-modifying therapies like hypomethylating agents and, crucially, evaluation for allogeneic stem cell transplantation.

30
Years of
Excellence

Trusted Worldwide

With patients from across the globe, we bring over three decades of medical expertise and hospitality to every individual who walks through our doors.  

Book a Free Certified Online Doctor Consultation

Doctors

Table of Contents

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Doctors

FREQUENTLY ASKED QUESTIONS

What differentiates leukemia from lymphoma if they are both blood cancers?

The primary difference lies in the cancer’s origin and central location. Leukemia originates in the bone marrow and primarily affects the blood and bone marrow, circulating as liquid cancer. Lymphoma also originates from blood cells, but typically forms solid tumors in lymph nodes and other lymphoid tissues.

Lymphoma is generally not considered an inherited condition passed directly from parent to child. While having a close family member with lymphoma may slightly increase risk, the vast majority of cases arise from acquired genetic mutations that occur during a person’s lifetime due to environmental factors, infections, or random errors in cell division.

The main types are Metabolic Acidosis (too much acid, often kidney-related), Metabolic Alkalosis (too much base), Respiratory Acidosis (too much carbon dioxide from slow breathing), and Respiratory Alkalosis (too little carbon dioxide from fast breathing).

You should see a nephrologist if blood tests show a persistent acid-base problem, especially if you have an existing kidney condition like Chronic Kidney Disease (CKD) or if the disorder is metabolic. They specialise in the complex role the kidneys play in regulating pH.

Nephrology focuses on the kidney’s role in the long-term regulation of base (bicarbonate) and acid excretion. Pulmonology focuses on the lung’s role in the rapid regulation of carbon dioxide levels. Both are vital, but handle different parts of the Acid-Base control system.

Spine Hospital of Louisiana

Let's Talk About Your Health

BUT WAIT, THERE'S MORE...

Leave your phone number and our medical team will call you back to discuss your healthcare needs and answer all your questions.

Let's Talk About Your Health
Your Comparison List (you must select at least 2 packages)